In evaluating patients with neuroendocrine tumors categorized based on tumor grade and Ki-67 index levels (<3%, 3%-20%, 21%-55%), we observed no difference in PFS across the groups. This evidence concerns the gene MKI67 and neuroendocrine neoplasm.